Peptide Medications and Cardiovascular Risk: Reading the Outcome Trials

A patient sat across from me last month, prescription in hand, and asked the question I hear more than almost any other: "Is this thing going to hurt my heart?" She'd read somewhere that any medication powerful enough to change your weight this fast must be doing something risky to your cardiovascular system. It's a fair worry. And it's exactly backward from what the best evidence now shows.

I'm Dr. Farhan Abdullah, an internal medicine physician and the Medical Director at Magnolia Functional Wellness here in Southlake. Before I ran a wellness clinic, I spent years as a hospitalist, which means I've stood at plenty of bedsides after heart attacks and strokes. So when I talk about the cardiovascular effects of the GLP-1 peptide medications, I'm not talking about them abstractly. I've watched what uncontrolled metabolic disease does to people. The good news is that we now have several large, well-run outcome trials telling us something genuinely reassuring, and I want to walk you through how to actually read them.

Why does this matter so much? Because a study that shows weight loss is one thing. A study that shows fewer people died, or had fewer heart attacks, is a completely different and far more important thing. Those are called cardiovascular outcome trials, and they're the gold standard. Let's get into what they found.

What a Cardiovascular Outcome Trial Actually Measures

Here's a distinction I wish more people understood before they start any injectable therapy. Most drug studies measure what we call surrogate endpoints: your weight dropped, your blood sugar improved, your blood pressure came down. Those are useful. But they're proxies. What you really want to know is whether the medication changes the events that matter, the heart attacks, the strokes, the deaths.

Measuring those things is expensive and slow. You need thousands of patients followed for years, because heart attacks, thankfully, don't happen to most people in any given month. The composite endpoint most of these trials use is called MACE, short for major adverse cardiovascular events, and it usually bundles three things: death from cardiovascular causes, nonfatal heart attack, and nonfatal stroke. When you see a trial report a hazard ratio below 1.0 for MACE, that means the treatment group had fewer of those events than placebo.

One more thing to watch for. Regulators originally required these trials just to prove the new diabetes drugs were safe for the heart, not that they helped. The bar was noninferiority, meaning "don't make things worse." What surprised everyone is that several of these medications didn't just clear that low bar. They showed superiority. They actively reduced events. That's rare, and it changed how we think about this entire class.

SUSTAIN-6 and LEADER: The Diabetes Trials That Started It

The first big signals came from patients with type 2 diabetes. In 2016, two trials landed in the same year, both published in the New England Journal of Medicine.

The LEADER trial, led by Steven Marso and colleagues, randomized 9,340 patients with type 2 diabetes and high cardiovascular risk to either liraglutide or placebo (Marso et al., NEJM 2016). Over a median of 3.8 years, the primary MACE outcome occurred in 13.0 percent of the liraglutide group versus 14.9 percent on placebo, a hazard ratio of 0.87. Cardiovascular death specifically dropped too. This wasn't a small study, and the effect held up.

The same year, SUSTAIN-6 tested semaglutide in 3,297 patients with type 2 diabetes, again versus placebo (Marso et al., NEJM 2016). Here the MACE reduction was even larger: 6.6 percent in the semaglutide group versus 8.9 percent on placebo, a hazard ratio of 0.74. That's roughly a 26 percent relative reduction in the risk of those hard events. Now, SUSTAIN-6 was designed as a safety trial and it was smaller, so I read that number with appropriate caution. But paired with LEADER, a picture was forming: this class of peptide medications seemed to be doing something for the cardiovascular system beyond glucose.

What I tell my patients is that the diabetes trials were the opening argument. The population was already high risk, already diabetic. The obvious next question was whether any of this applied to people carrying extra weight who hadn't yet developed diabetes. That's a much bigger group of people, and honestly, it's a lot of the folks who walk into my clinic.

SELECT: The Trial That Changed the Conversation

Then came SELECT, and it's the one I spend the most time on with patients. Published in 2023 by Michael Lincoff and a large group of investigators, this trial enrolled 17,604 patients (Lincoff et al., NEJM 2023). Every one of them had established cardiovascular disease and a body mass index of 27 or higher. And here's the key design choice: none of them had diabetes.

They received either once-weekly semaglutide at 2.4 mg or placebo, and they were followed for a mean of nearly 40 months. The primary cardiovascular endpoint, that same composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke, occurred in 6.5 percent of the semaglutide group versus 8.0 percent on placebo. The hazard ratio was 0.80, with a tight confidence interval and a p-value below 0.001. In plain terms, a 20 percent reduction in the risk of major cardiovascular events, in people who did not have diabetes.

Think about what that means. For the first time, we had strong evidence that treating obesity itself, in someone with heart disease but normal blood sugar, reduced their odds of a heart attack or stroke. That's not a weight number on a scale. That's a person not ending up in a hospital bed like the ones I used to round on. When a trial that large, that rigorous, lands that cleanly, it deserves your attention.

Was it a perfect trial? No trial is. The discontinuation rate was higher in the semaglutide group, largely from gastrointestinal side effects, and the population was mostly men and mostly white, which limits how confidently we extend the findings to everyone. Good medicine means holding both truths at once: this is a landmark result, and it still has boundaries.

How I Read These Numbers in the Clinic

So what do you do with all this? A few principles guide how I use outcome data with real patients at Magnolia Functional Wellness.

First, relative risk and absolute risk are not the same thing, and marketing loves to blur them. A 20 percent relative reduction sounds enormous. The absolute difference in SELECT was about 1.5 percentage points over roughly three years. Both numbers are true. Which one matters more depends entirely on how high your baseline risk already is. Someone with prior heart disease has a lot more to gain than someone with none, which is precisely why SELECT enrolled the higher-risk group.

Second, these were studies of specific, FDA-approved branded products at specific doses. Ozempic and Wegovy are FDA-approved products, and semaglutide is the drug substance they're built on. When I counsel someone, I'm careful not to stretch trial results onto situations the trials never tested. The evidence is strong for what was actually studied.

Third, none of this replaces the fundamentals. Not one of these trials asked patients to stop moving, stop eating well, or stop managing blood pressure and cholesterol. The medication was added on top of standard care. I've seen people treat a prescription like permission to ignore everything else, and that's a mistake. The peptide is a tool, a good one, inside a larger plan.

What This Looks Like Before We Prescribe

Reading trials is one half of the job. The other half is figuring out whether a given medication fits the person sitting in front of me, and that starts with actual data, not a guess. Before anyone begins peptide medication therapy at our clinic, we run a baseline workup: a full metabolic panel, a lipid profile, an A1c to see where blood sugar sits, and a careful history of any cardiac events, family history, and current medications. If someone already carries a diagnosis of coronary disease or has had a prior stroke, that changes the calculus, and frankly it often strengthens the case, because those are the patients the outcome trials showed benefited most.

Then we monitor. I've had patients feel so good a few months in that they assume the labs don't matter anymore. They do. We recheck, we adjust the dose, and we watch for the side effects that actually show up in practice, mostly the gastrointestinal ones, occasionally gallbladder issues, rarely anything more serious. Titration is slow on purpose. There's no prize for rushing to the top dose, and plenty of misery to be had by trying.

I'll admit a bias here. Living and practicing in Texas, where the summer heat alone keeps people indoors and the barbecue culture is what it is, I see a lot of metabolic disease that's been building quietly for years. When a therapy comes along with outcome data this solid, I pay attention. But attention isn't the same as a blank prescription. The workup is what tells us whether the trial evidence actually applies to you.

Where the Field Is Heading

The story isn't finished. Tirzepatide, a dual-receptor peptide medication, has already transformed weight outcomes, and its dedicated cardiovascular outcome data continues to mature. Researchers are also digging into why these drugs help the heart. Is it the weight loss? The reduction in inflammation? Direct effects on blood vessels? Almost certainly some combination, and untangling it is active, fascinating work.

What I want you to take from all this is simple. The question my patient asked, whether these medications hurt the heart, has a better answer than it did even a few years ago. In the populations that were actually studied, the evidence points the other way. But the right medication for you depends on your history, your risks, and your goals, and that's a conversation to have with a physician who'll read the trials honestly rather than the headlines. If you're weighing peptide medication therapy and want someone to walk through your cardiovascular picture with you, that's exactly the kind of visit we do here in Southlake.

By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX